In addition, the proliferative effect of NET was completely abolished after pre-treatment with fulvestrant, validating that the progestin-dependent increased breast cancer cell viability is conveyed through the ERα signaling pathway (Figure 5B). This evidence concerns the gene ESR1 and breast carcinoma.